Ann: First-in-human clinical trials begin in Singapore, page-15

https://unauthorised investment advice/news/top-10-at-10-its-a-right-royal-knees-up-for-osteopore-today/

The state of Australian financial media reporting (crappy automated screen scrapes with a little $70K a year over-worked overseer).

Perhaps given the doom and gloom recently on OSX, the price rise, following the price falls, warranted as OSX recently gained Singapore and Vietnamese approvals of course, and now, contrary to the impending delisting painted on these threads by the very vocal ignorant on these threads (it was only temporarily suspended along with lots of other micro-cap stocks that occassionally get suspended for reporting failures), gaining further business confidence from very real human trials with Singapore's leading public reseach agency - and lets not forget its ongoing negotiations for a joint venture with Temasek (the leading domestic business vehicle for Singapore state funds) backed Innoventure.

These stocks become binary like options at this risky end, with large share price rewards if they survive vs complete loss of capital if they don't. This deal implies more confidence in the former. OSX back channels to the Singapore state via research and possible investment contracts/JV's were arguably over-looked in its recent pricing to failure.